T. Rowe Price Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-81,773
| Closed | -$278K | – | 2611 |
|
|
2018
Q3 | $278K | Buy |
81,773
+28,781
| +54% | +$97.8K | ﹤0.01% | 2368 |
|
|
2018
Q2 | $199K | Buy |
52,992
+97
| +0.2% | +$364 | ﹤0.01% | 2453 |
|
|
2018
Q1 | $216K | Buy |
52,895
+175
| +0.3% | +$715 | ﹤0.01% | 2375 |
|
|
2017
Q4 | $245K | Buy |
52,720
+26,000
| +97% | +$121K | ﹤0.01% | 2331 |
|
|
2017
Q3 | $190K | Sell |
26,720
-11,800
| -31% | -$83.9K | ﹤0.01% | 2407 |
|
|
2017
Q2 | $278K | Sell |
38,520
-5,726
| -13% | -$41.3K | ﹤0.01% | 2272 |
|
|
2017
Q1 | $273K | Hold |
44,246
| – | – | ﹤0.01% | 2294 |
|
|
2016
Q4 | $259K | Sell |
44,246
-12,700
| -22% | -$74.3K | ﹤0.01% | 2297 |
|
|
2016
Q3 | $302K | Buy |
56,946
+21,100
| +59% | +$112K | ﹤0.01% | 2211 |
|
|
2016
Q2 | $237K | Sell |
35,846
-54
| -0.2% | -$357 | ﹤0.01% | 2262 |
|
|
2016
Q1 | $168K | Buy |
35,900
+17,400
| +94% | +$81.4K | ﹤0.01% | 2324 |
|
|
2015
Q4 | $93K | Sell |
18,500
-11,300
| -38% | -$56.8K | ﹤0.01% | 2433 |
|
|
2015
Q3 | $105K | Hold |
29,800
| – | – | ﹤0.01% | 2400 |
|
|
2015
Q2 | $297K | Buy |
29,800
+6,100
| +26% | +$60.8K | ﹤0.01% | 2200 |
|
|
2015
Q1 | $302K | Sell |
23,700
-1,080
| -4% | -$13.8K | ﹤0.01% | 2185 |
|
|
2014
Q4 | $351K | Sell |
24,780
-3,620
| -13% | -$51.3K | ﹤0.01% | 2114 |
|
|
2014
Q3 | $391K | Hold |
28,400
| – | – | ﹤0.01% | 2044 |
|
|
2014
Q2 | $437K | Hold |
28,400
| – | – | ﹤0.01% | 2007 |
|
|
2014
Q1 | $484K | Hold |
28,400
| – | – | ﹤0.01% | 1929 |
|
|
2013
Q4 | $368K | Sell |
28,400
-14,400
| -34% | -$187K | ﹤0.01% | 2043 |
|
|
2013
Q3 | $432K | Buy |
42,800
+24,600
| +135% | +$248K | ﹤0.01% | 1945 |
|
|
2013
Q2 | $136K | Buy |
+18,200
| New | +$136K | ﹤0.01% | 2280 |
|